Bedrijfsoverzicht
Avalo Therapeutics, Inc. is a clinical stage biotechnology company dedicated to developing therapies aimed at treating immune dysregulation within the United States market. The firm operates specifically within the healthcare sector and the biotechnology industry, which typically involves high levels of research and development expenditure prior to commercial product launches. As of the latest data, the company carries a market capitalization of $311.29M, reports annual revenue of $59,000, and employs 33 individuals to execute its strategic initiatives. The market cap figure of $311.29M combined with minimal revenue of $59,000 indicates that the company's valuation is derived primarily from the potential of its pipeline assets rather than current operational cash flows. This disparity suggests the market is pricing in significant future commercialization potential from its lead asset, AVTX-009, which is currently in a phase 2 clinical trial, rather than established business performance. The scale of the operation, defined by a small workforce of 33 employees, reflects the typical lean structure of a clinical stage entity focused on advancing a specific therapeutic candidate rather than running a broad commercial manufacturing and sales organization.
Financiële gezondheid
The company generated revenue of $59,000 over the trailing twelve months, while reporting a net income of $-78,259,000 and an EBITDA of $-72,581,000, highlighting a substantial gap between nominal revenue and substantial losses. This significant divergence between the negligible revenue and the multi-million dollar negative net income reveals a cost structure dominated by research and development expenses, clinical trial costs, and general administrative overheads typical of early-stage biotechnology firms. The free cash flow stands at $-17,263,124, which indicates that the company is currently consuming cash reserves to fund its operations and development programs without generating positive operating cash flow. Despite the negative cash flow, the company maintains a cash balance of $98.34M, providing a substantial liquidity buffer against its current burn rate. The balance sheet shows a debt level of $427,000 against a debt-to-equity ratio of 0.51, suggesting a relatively conservative leverage profile despite the heavy reliance on equity financing. The current ratio is reported at 8.14, which signifies a highly liquid short-term position where current assets significantly exceed current liabilities. Furthermore, the return on equity is -72.4% and the return on assets is -34.1%, metrics that indicate management is currently generating negative returns on the capital invested, a common characteristic for clinical stage companies that have not yet achieved commercial revenue milestones.
Waarderingsbeoordeling
The company does not have a trailing P/E ratio as earnings are negative, while the forward P/E is listed as -4.50, a metric that is technically undefined for loss-making entities but reflects the market's pricing mechanism based on projected future earnings potential rather than historical performance. The price-to-book ratio is 3.05, indicating that the market values the company at more than three times its net book value, a premium often justified by the intellectual property and potential of the pipeline rather than tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 5276.11 and the EV/EBITDA of -2.94 further illustrate that traditional valuation models are not applicable due to the lack of profitability and sales scale. The stock's 52-week trading range spans from a low of $3.39 to a high of $20.72, providing a clear view of the price volatility experienced over the last year. The current price sits at a level that reflects significant compression from the 52-week high of $20.72, illustrating the market's reaction to recent performance data. The beta value of 0.94 suggests that the stock's price volatility closely mirrors that of the broader market, moving in tandem with general market trends rather than exhibiting extreme idiosyncratic swings.
Growth & Income
Revenue growth year-over-year is -69.3%, while earnings growth is listed as N/A, indicating that the company is currently in a contraction phase regarding top-line sales as it pivots resources toward clinical development rather than commercial expansion. Because the company is in a pre-revenue or minimal revenue stage, earnings cannot grow faster than revenue in the traditional sense, as both are heavily influenced by the timing of clinical milestones and regulatory approvals rather than sales volume. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings and cash reserves are reinvested into the business to fund research and development activities. The overall growth and income profile is characterized by negative revenue growth and a complete absence of dividend income, reflecting the standard lifecycle of a clinical stage biotechnology company focused on asset advancement rather than shareholder distributions.